Oversubscribed issue of shares in Ortoma

Published May 15, 2013

Ortoma have raised a total of 4 million SEK in a funding round that was closed this summer. It has been oversubscribed and many new investors are welcomed, as owners, as well as existing owners who have strengthened their positions in the company. Ortoma has been working with Sedermera Fondkommission AB as well as GU Holding AB and Ortnova Intressenter AB, to secure the financing round.
–  We are very pleased with the great interest the investors have shown in Ortoma and are now able to continue our development as well as our clinical collaborations, says Klementina Österberg, chairman of Ortoma, as well as CEO for GU Holding, one the main owners of the company..
–  We can now continue our development work and begin our work to comply with QA – standards in the medtech-industry including CE certification of Ortoma Plan, says Bertil G. Larsson, CEO of Ortoma. Our goal in developing Ortoma Treatment Solution is to assist surgeons to improve and assure best possible implant positioning in prosthesis surgery of joint replacement using latest cutting-edge technology.
Together with the company’s founder, Dr. Matts Andersson, and orthopedic surgeons Professor Tommy Hansson, Sahlgrenska University Hospital, and Associate Professor Gunnar Flivik, at Skåne University Hospital, Ortoma is developing new therapies for hip, knee and spinal surgery.
The goal is to improve the surgical outcomes of patients by developing improved treatments in orthopedics based on high-tech solutions. Ortoma Plan a 3D-pre operative planning system will be clinically evaluated at Skåne University Hospital during the summer.
For more information:
Klementina Österberg, CEO GU Holding and Chairman Ortoma, [email protected] or +46 70 440 1190.
Bertil G. Larsson, CEO Ortoma, [email protected] or +46 70 299 7510.

About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Nasdaq First North Growth Market Stockholm.